Skip to content
Company Analysis

Genetic Technologies Ltd GENE

A comprehensive view of key metrics, scores, and financial health for Genetic Technologies Ltd

Overview of Genetic Technologies Limited

GENE
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics
Genetic Technologies Limited (GENE), in the Diagnostics & Research industry.
$ -
-
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Completeness: 6%
Confidence: 2%
Updated: Mar 8
Top Beats

Quick Facts

Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$7.7M
-25.9%%
Gross Profit
$3.9M
-35.1%%
Operating Income (GAAP)
$-6.5M
37.2%%
EBITDA
$-11.4M
-2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
50.9%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
Analysis based on partial data. Some metrics unavailable for complete assessment.
1
Active Leaks
1/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Genetic Technologies Ltd's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
25
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
25
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 64% Coverage
Trade-Off Triangle Visualization A ternary plot showing GENE's balance between Growth (48.7%), Profitability (23.1%), and Safety (28.3%). Growth 49% Safety 28% Profitability 23%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
52
Key Signals
Revenue CAGR 3Y 2.99 98p Rev Growth YoY -25.9% 12p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (2.99, 98th percentile)
  • Conservative leverage compared to industry peers
Risks
  • Rev Growth YoY in bottom 20% of peers (-25.9%)

Profitability

24th percentile vs peers
25
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

30th percentile vs peers
30
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Genetic Technologies Ltd.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000